The modern global health system has developed a disturbing dual speed. When a disease threatens the economic stability of wealthy nations, science accelerates, funding floods in and political leaders act with near-military urgency. When a disease is geographically distant, politically inconvenient or confined largely to poorer regions, the system reverts to hesitation, fragmentation and chronic underinvestment.
Ebola is the clearest example of this asymmetry. COVID-19 is the exception that proves the rule.
Today, as the World Health Organization warns of worsening Ebola transmission in the Democratic Republic of Congo (DRC), particularly in the conflict-ridden east where insecurity has made basic outbreak control extremely difficult, the world is once again witnessing a familiar cycle. Dr Tedros Adhanom Ghebreyesus has described the situation as a “catastrophic collision of disease and conflict”, emphasizing that health workers cannot isolate cases or build trust while violence persists. With approximately 220 suspected deaths already reported in the current outbreak, the crisis is not only biological; it is structural, political and deeply international.
Yet beneath the immediate emergency lies a longer, more uncomfortable truth: the world still has not built a truly accessible, globally embedded Ebola vaccination system, despite having the scientific tools to do so.
Ebola
The development of an effective Ebola vaccine is often presented as a public health success story, and in strictly scientific terms, it is. The rVSV-ZEBOV vaccine (Ervebo) demonstrated extraordinary efficacy in clinical trials during the 2014–2016 West African outbreak. A pivotal study published in the New England Journal of Medicine in 2015 showed near-complete protection among vaccinated contacts in Guinea, using a “ring vaccination” approach designed to contain transmission chains.
By 2019, the vaccine received regulatory approval in Europe and the United States. During the 2018–2020 Ebola outbreak in eastern DRC, more than 300,000 people were vaccinated under emergency deployment, contributing significantly to outbreak control.
But these milestones conceal a more troubling reality. Ebola vaccination has remained largely reactive rather than preventive. Instead of being integrated into routine immunization strategies in high-risk regions, it is deployed only after outbreaks begin. Production capacity remains limited, global stockpiles are tightly managed, and distribution depends heavily on emergency coordination mechanisms that are often slowed by insecurity and logistics.
This is not a failure of science. It is a failure of sustained political commitment.
COVID-19
The contrast with COVID-19 is not subtle; it is structural. Within approximately 12 months of SARS-CoV-2 being identified, multiple vaccines were developed, tested, authorized and mass-produced. By December 2020, emergency authorizations began rolling out in the United Kingdom and United States. By mid-2021, global vaccination campaigns were underway at unprecedented scale. Today, more than 13 billion COVID-19 vaccine doses have been administered worldwide, according to WHO estimates.
This speed was not accidental. It was engineered through extraordinary political and financial mobilization.
The United States launched Operation Warp Speed with an estimated budget exceeding $18 billion, combining direct funding, procurement guarantees and risk-sharing arrangements with pharmaceutical companies. The European Union, United Kingdom, China and other major economies implemented parallel strategies, securing advance purchase agreements that effectively removed commercial risk for manufacturers.
This financial architecture mattered. It transformed vaccine development from a high-risk scientific endeavour into a guaranteed global market. Pharmaceutical companies could scale production before final approvals because demand had already been politically and financially locked in.
The result was unprecedented: vaccines developed in record time, produced at industrial scale and distributed across continents within a year.
The Ebola Gap
Ebola never triggered this level of urgency. Not because it is less deadly; its case fatality rate in some outbreaks has reached 50% or higher, but because it lacks global economic “gravity”.
Since its discovery in 1976, Ebola has caused repeated outbreaks, primarily in Central and West Africa. The 2014–2016 West African epidemic alone resulted in over 28,000 cases and more than 11,000 deaths, making it the largest Ebola outbreak in history. It also exposed the fragility of global preparedness systems and the dangers of delayed response.
Yet after this catastrophe, investment in permanent Ebola preparedness remained modest. Vaccine production capacity did not expand to meet potential future demand. Stockpiles were not scaled to global emergency levels. Instead, Ebola preparedness remained largely dependent on donor funding cycles, emergency appeals and short-term commitments.
Organizations like the Coalition for Epidemic Preparedness Innovations (CEPI) have worked to change this trajectory, but their annual budgets, measured in hundreds of millions, are negligible compared to the trillions mobilized during COVID-19.
The disparity reveals a fundamental truth about global health governance: diseases that primarily affect low-income countries are structurally deprioritized, even when their lethality is high.
Pharmaceutical Incentives and Neglected Disease Market Failure
At the centre of this imbalance lies the economics of vaccine development. Vaccines require enormous upfront investment: laboratory research, clinical trials, regulatory approval, manufacturing infrastructure and global distribution systems. For diseases like COVID-19, where demand spans every high-income country simultaneously, the return on investment is clear and immediate.
For Ebola, the market is fragmented and uncertain. Outbreaks are sporadic, geographically concentrated and difficult to predict. Without guaranteed purchase commitments from wealthy governments, pharmaceutical companies face limited financial incentive to scale production or invest in long-term capacity.
This is a classic market failure in global health: the diseases that impose the highest burden on vulnerable populations are often the least profitable to address.
COVID-19 temporarily overcame this failure through unprecedented state intervention. Governments essentially became the primary buyers of vaccines before they existed, removing commercial uncertainty. Ebola never received this structural correction at scale.
Conflict, Fragility and the Collapse of Response Systems
The current Ebola outbreak in eastern DRC illustrates how health crises are magnified by instability. Unlike previous outbreaks that were primarily rural or geographically contained, the current situation unfolds in a region marked by armed conflict, displacement and weak state presence. Health workers face physical insecurity, while communities often distrust official interventions due to long-standing political grievances.
In such environments, even highly effective vaccines cannot function optimally. Cold-chain logistics break down. Vaccination teams are restricted in movement. Contact tracing becomes incomplete or impossible. Community engagement, a cornerstone of Ebola control, collapses under the weight of insecurity.
This is why Dr Tedros’ warning is so significant. The phrase “cannot build community trust or isolate the sick while bombs are falling” captures a central reality of modern epidemic response: biology cannot be separated from geopolitics.
The Equity Deficit in Global Health Priorities
The deeper issue is not simply Ebola versus COVID-19. It is the broader architecture of global health equity. COVID-19 demonstrated that when wealthy nations perceive direct threat, global coordination becomes rapid and decisive. Intellectual property rules are debated, manufacturing is scaled across continents and supply chains are redirected within months.
Ebola demonstrates the opposite: when a disease remains geographically distant from economic centers of power, response systems remain fragmented, underfunded and reactive.
This is not an argument about intent. It is an argument about incentives. The global system is designed in such a way that urgency correlates strongly with economic exposure.
The consequences are visible in preventable mortality. The 2014–2016 Ebola outbreak alone killed over 11,000 people. Subsequent outbreaks have added thousands more. Many of these deaths occurred despite the existence of effective vaccines and improved treatment protocols.
Conclusion
The world has already proven it can respond to pandemics with extraordinary speed. COVID-19 showed that scientific barriers are not the limiting factor. Political will and financial coordination are.
The persistence of Ebola outbreaks in regions like eastern DRC reveals what happens when that will is inconsistent and selectively applied. The vaccine exists. The science works. What is missing is the system that ensures it is always available, always deployable and always prioritized, regardless of geography or global attention.
A credible global health future would treat Ebola not as an episodic emergency but as a permanently anticipated risk. It would expand vaccine manufacturing capacity in and around Africa, strengthen regional stockpiles and fund outbreak response mechanisms that do not collapse under insecurity. Most importantly, it would decouple life-saving preparedness from global media cycles and economic self-interest.
Because the real lesson of COVID-19 is not just that rapid vaccine development is possible. It is that the world only moves quickly when it feels personally threatened.
And until that changes, diseases like Ebola will continue to exploit the gaps between what science can do and what politics chooses to do.

